AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9850014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CEF) followed by mitomycin and vinblastine (MV)
Number of subjects: 303
Study 9850014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CEF)
Number of subjects: 303
Study 9850014 — intervention group
Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 303
Study 9850014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 303
Study 8014492 — intervention group
Group type: EXPERIMENTAL
Intervention: ethambutol (15 mg/kg)
Number of subjects: 60
Study 8014492 — intervention group
Group type: EXPERIMENTAL
Intervention: clofazimine (200 mg)
Number of subjects: 60
Study 8014492 — intervention group
Group type: EXPERIMENTAL
Intervention: rifampin (600 mg)
Number of subjects: 60
Study 2509917 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (2 million units) subcutaneously three times weekly for six months
Number of subjects: 41
Study 2509917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 786350 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation technique using nitrous oxide and oxygen, with tubocurarine and fentanyl
Number of subjects: 2
Study 786350 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation technique using nitrous oxide, oxygen and halothane
Number of subjects: 2
Study 31185058 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist contraceptive support via telephone or face-to-face consultation at 2–4 weeks and 3 months post-abortion
Number of subjects: 569
Study 31185058 — intervention group
Group type: COMPARATOR
Intervention: Standard care (advice to follow up with general practitioner or contraceptive clinic)
Number of subjects: 569
Study 31185058 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist contraceptive support
Number of subjects: 569
Study 31185058 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 569
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 10 mg single dose
Number of subjects: 86
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 25 mg single dose
Number of subjects: 86
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 50 mg single dose
Number of subjects: 86
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 10 mg for 21 days
Number of subjects: 86
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 25 mg for 21 days
Number of subjects: 86
Study 29125703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 50 mg for 21 days
Number of subjects: 86
Study 29125703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29786223 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Compression Plate (PCCP)
Number of subjects: 70
Study 29786223 — intervention group
Group type: COMPARATOR
Intervention: Hollow Compression Screw
Number of subjects: 70
Study 25319690 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional pictures
Number of subjects: 586
Study 25319690 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional pictures
Number of subjects: 586
Study 25319690 — intervention group
Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 586
Study 25319690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus to amygdala connection
Number of subjects: 586
Study 22205605 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA eye drops for 6 weeks
Number of subjects: 0
Study 22205605 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 0
Study 22205605 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA in compartmental culture
Number of subjects: 0
Study 22205605 — intervention group
Group type: COMPARATOR
Intervention: Vehicle in compartmental culture (Control)
Number of subjects: 0
Study 19615755 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 181
Study 19615755 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based trajectory modeling
Number of subjects: 181
Study 19615755 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief screening for maternal depressive symptoms
Number of subjects: 181
Study 19615755 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 181
Study 16806740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 51
Study 16226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete androgen blockade initiated 2 months prior to starting radiotherapy and stopped at the completion of radiotherapy
Number of subjects: 0
Study 16226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant androgen suppression started at the end of the radiotherapy and continued indefinitely
Number of subjects: 0
Study 16226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete androgen blockade for two months before and during radiation followed by 24 additional months of LHRH analogue alone
Number of subjects: 0
Study 16226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression with LHRH analogue given during and for 3 years after external irradiation
Number of subjects: 0
Study 16226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment in localized prostate cancer (T1‐2 N0) with poor prognostic factors: Gleason score 8‐10, PSA>20 ng/ml
Number of subjects: 0
Study 12365874 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10464863 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis patients (HDp)
Number of subjects: 29
Study 10464863 — intervention group
Group type: COMPARATOR
Intervention: PPD (‐) HDp
Number of subjects: 29
Study 10464863 — intervention group
Group type: COMPARATOR
Intervention: PPD (+) HDp
Number of subjects: 29
Study 10464863 — intervention group
Group type: COMPARATOR
Intervention: Nutritional parameters
Number of subjects: 29
Study 10464863 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL subtype percentages and absolute counts
Number of subjects: 29
Study 7793217 — intervention group
Group type: EXPERIMENTAL
Intervention: ketobemidone 5 mg
Number of subjects: 120
Study 7793217 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 120
Study 7793217 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 40 mg
Number of subjects: 120
Study 7793217 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 1778085 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (25 mg)
Number of subjects: 129
Study 1778085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus Triamterene (25 mg + 50 mg)
Number of subjects: 129
Study 1778085 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from Chlorthalidone plus Triamterene to Chlorthalidone
Number of subjects: 129
Study 1778085 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from Chlorthalidone to Chlorthalidone plus Triamterene
Number of subjects: 129
Study 7249547 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-propranolol (0.1 mg/kg)
Number of subjects: 0
Study 7249547 — intervention group
Group type: EXPERIMENTAL
Intervention: D-propranolol (1.0 mg/kg)
Number of subjects: 0
Study 7249547 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-propranolol
Number of subjects: 0
Study 7249547 — intervention group
Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 0
Study 7249547 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-propranolol and D-propranolol
Number of subjects: 0
Study 6339649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin-tobramycin
Number of subjects: 0
Study 6339649 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin-tobramycin
Number of subjects: 0
Study 6339649 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin-placebo
Number of subjects: 0
Study 30629024 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 861
Study 30629024 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 861
Study 31065119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 60
Study 31065119 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 10 micrograms
Number of subjects: 60
Study 26673802 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.5 mcg kg⁻¹
Number of subjects: 0
Study 26673802 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 1.0 mcg kg⁻¹
Number of subjects: 0
Study 26673802 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 1.5 mcg kg⁻¹
Number of subjects: 0
Study 24623515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature walking route (NW)
Number of subjects: 94
Study 24623515 — intervention group
Group type: EXPERIMENTAL
Intervention: Built walking route (BW)
Number of subjects: 94
Study 24623515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (NW and BW)
Number of subjects: 94
Study 24623515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 22353042 — intervention group
Group type: EXPERIMENTAL
Intervention: Melamine foam sponge
Number of subjects: 27
Study 22353042 — intervention group
Group type: COMPARATOR
Intervention: Cotton wool bud
Number of subjects: 27
Study 20004526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose outside the prostate (68-78 Gy)
Number of subjects: 352
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet and antithrombotic agents
Number of subjects: 0
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion therapy
Number of subjects: 0
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapies
Number of subjects: 0
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric arterial ischemic stroke studies
Number of subjects: 0
Study 17425493 — intervention group
Group type: EXPERIMENTAL
Intervention: International study
Number of subjects: 0
Study 15657070 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone 20 mg and eight sessions of standardized physiotherapy
Number of subjects: 80
Study 15657070 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone 20 mg alone
Number of subjects: 80
Study 15657070 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection and eight sessions of standardized physiotherapy
Number of subjects: 80
Study 15657070 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection alone
Number of subjects: 80
Study 12651995 — intervention group
Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 101
Study 12651995 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive support
Number of subjects: 101
Study 12651995 — intervention group
Group type: COMPARATOR
Intervention: Alone
Number of subjects: 101
Study 12651995 — intervention group
Group type: COMPARATOR
Intervention: Interaction
Number of subjects: 101
Study 10592533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl (Eufans) 600 mg once daily for 14 consecutive days per month for 2 months (P, n = 10; PV, n = 8; PVE, n = 7)
Number of subjects: 43
Study 10592533 — intervention group
Group type: COMPARATOR
Intervention: No treatment (matched-control, n = 6 for each category)
Number of subjects: 43
Study 10592533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (after first course T1)
Number of subjects: 43
Study 10592533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (after second course T2)
Number of subjects: 43
Study 10592533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (T2)
Number of subjects: 43
Study 8708166 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS) 100 cc with Unweighted tube (UNW)
Number of subjects: 83
Study 8708166 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS) 100 cc with Weighted tube (WEI)
Number of subjects: 83
Study 8708166 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (EMY) 200 mg with Weighted tube (WEI)
Number of subjects: 83
Study 8708166 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MET) 10 mg with Weighted tube (WEI)
Number of subjects: 83
Study 2036759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iothalamate
Number of subjects: 0
Study 2036759 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study 2036759 — intervention group
Group type: COMPARATOR
Intervention: Sodium/methylglucamine ioxaglate
Number of subjects: 0
Study 7041039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 100
Study 7041039 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 31747009 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatux‐M 1.25 mg/kg every 2 weeks intravenously
Number of subjects: 260
Study 31747009 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatux‐M monotherapy
Number of subjects: 260
Study 31747009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Depatux‐M with temozolomide
Number of subjects: 260
Study 31747009 — intervention group
Group type: COMPARATOR
Intervention: Control arm (temozolomide or lomustine)
Number of subjects: 260
Study 31570211 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support-Tai Chi (BWS-TC)
Number of subjects: 28
Study 31570211 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 27859645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 77
Study 27859645 — intervention group
Group type: COMPARATOR
Intervention: Pediatric colonoscope (PDC)
Number of subjects: 77
Study 26507718 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (surgery using tension band wiring or plate fixation)
Number of subjects: 0
Study 26507718 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (early range of motion as tolerated)
Number of subjects: 0
Study 26507718 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0
Study 26507718 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 0
Study 23674047 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 39
Study 23674047 — intervention group
Group type: COMPARATOR
Intervention: Traditional-reperfusion
Number of subjects: 39
Study 21546857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-α (IFN)
Number of subjects: 117
Study 21546857 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 117
Study 20040824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Number of subjects: 714
Study 17696259 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg/d
Number of subjects: 61
Study 17696259 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LVD) 100 mg/d
Number of subjects: 61
Study 17696259 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LVD) switched to Entecavir (ETV) 1.0 mg/d
Number of subjects: 61
Study 15145968 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 1-minute infusion
Number of subjects: 8
Study 15145968 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 1-hour infusion
Number of subjects: 8
Study 15145968 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 3-hour infusion
Number of subjects: 8
Study 11444340 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (n=30)
Number of subjects: 61
Study 11444340 — intervention group
Group type: COMPARATOR
Intervention: PG F2alpha (n=31)
Number of subjects: 61
Study 11444340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 10363123 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical intrafallopian insemination (IFI)
Number of subjects: 30
Study 10363123 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 30
Study 7491044 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU intravenous infusion for 1 hour)
Number of subjects: 622
Study 7491044 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus aspirin
Number of subjects: 622
Study 7491044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day for 10 days)
Number of subjects: 622
Study 7491044 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment (control group)
Number of subjects: 622
Study 7020563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum beer (2 litres, carbohydrate content approximately 5%, alcohol concentration 2.24 g/dl-2.8% v/v)
Number of subjects: 8
Study 7020563 — intervention group
Group type: COMPARATOR
Intervention: Control solution (2 litres providing a similar carbohydrate load)
Number of subjects: 8
Study 7020563 — intervention group
Group type: COMPARATOR
Intervention: Gin and tonic mixture
Number of subjects: 8
Study 31021140 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about the harmful impact of gender stereotypes in STEM and strategies for coping with stereotype threat
Number of subjects: 199
Study 31021140 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 199
Study 31021140 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 199
Study 31081522 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose ticagrelor (90 mg LD, then 45 mg twice daily)
Number of subjects: 80
Study 31081522 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel (150 mg once daily)
Number of subjects: 80
Study 30036076 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended release (MPH‐MLR)
Number of subjects: 200
Study 27455854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.2 g/kg bw
Number of subjects: 350
Study 27455854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.4 g/kg bw
Number of subjects: 350
Study 27455854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 24929795 — intervention group
Group type: EXPERIMENTAL
Intervention: Probinul-neutro®
Number of subjects: 30
Study 24929795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23059741 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axis view combined with out-of-plane needle tip approach (dynamic needle tip positioning)
Number of subjects: 59
Study 23059741 — intervention group
Group type: COMPARATOR
Intervention: Long axis view combined with in-plane needle tip approach
Number of subjects: 59
Study 20528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA)
Number of subjects: 27
Study 20528977 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 27
Study 20528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 27
Study 18473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting QTd in Group 2 (significant CAD)
Number of subjects: 88
Study 18473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress QTd in Group 1 (no stenosis)
Number of subjects: 88
Study 18473373 — intervention group
Group type: COMPARATOR
Intervention: Adenosine stress QTd in Group 2 (significant CAD)
Number of subjects: 88
Study 18473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting QTd in patients with significant CAD
Number of subjects: 88
Study 18473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting QTd (4th Quartile)
Number of subjects: 88
Study 18473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta QTd (1st and 2nd Quartiles)
Number of subjects: 88
Study 15718288 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine coadministration
Number of subjects: 20
Study 15718288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12886207 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophase impression material
Number of subjects: 10
Study 12886207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid impression material
Number of subjects: 10
Study 12886207 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic dual-arch trays with monophase material
Number of subjects: 10
Study 12886207 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal dual-arch trays
Number of subjects: 10
Study 12886207 — intervention group
Group type: COMPARATOR
Intervention: Sequence of pouring impressions
Number of subjects: 10
Study 10589403 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoconazole 1-BSR (single dose)
Number of subjects: 205
Study 10589403 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 7 (seven-day treatment)
Number of subjects: 205
Study 8789864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative extraconal bupivacaine injection
Number of subjects: 40
Study 1586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 5 mg ISDN
Number of subjects: 12
Study 1586374 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 5 mg ISDN
Number of subjects: 12
Study 6086974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic alternating chemotherapy with a four-drug combination of COMP
Number of subjects: 0
Study 6086974 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination of VP-16, adriamycin and ACNU (VAN)
Number of subjects: 0
Study 6086974 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chest irradiation
Number of subjects: 0
Study 6086974 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0
Study 30420184 — intervention group
Group type: EXPERIMENTAL
Intervention: LDS + EZE
Number of subjects: 100
Study 30420184 — intervention group
Group type: EXPERIMENTAL
Intervention: LDS + ALP
Number of subjects: 100